Probi® takes over all distribution of BLIS K12™ and BLIS M18™ in the US and Canada after Blis Technologies distribution agreement with its previous partner ends. Since 2021, Probi has a partnership for the dairy-free production and distribution of Blis’ products. The technology transfer of the manufacturing has been completed, and Probi will be the sole distributor of bulk products for BLIS K12™ and BLIS M18™ on the North American market.
Since July 2021, Probi and Blis Technologies have a long-term strategic partnership for the distribution and manufacture of BLIS® probiotic strains in oral health. Blis Technologies has now ended the distribution agreement with a previous partner, which means that as of August 1, 2023, Probi will be the sole distributor of BLIS K12™ and BLIS M18™ ingredients in the USA and Canada.
Probi has also completed the technology transfer for the production of dairy-free BLIS K12™ and BLIS M18™ in their manufacturing facility in Redmond, Washington, which means that Probi has full-scale production capacity of both bulk powder and product applications of the strains.
“Oral health is a growing niche in probiotics. We will be alone in the US with dairy-free oral probiotics, and we see great growth potential of the BLIS strains. Our ability to offer customers both bulk powder and customized applications provide differentiated solutions to meet consumer demand,” says Diane Alexander, North America Sales Director, Probi AB.
“Since 2021, we have had a close and very rewarding collaboration with Probi. We saw a need to consolidate our representation in the North American market and it was therefore natural to focus our distribution through Probi. Probi will work with our existing customers providing ongoing support and continuity of supply, this will include both the current source of BLIS K12™ and BLIS M18™ but also the option of dairy-free versions from the Probi facility,” says Brian Watson, CEO of Blis Technologies.
Streptococcus salivarius BLIS K12™ and Streptococcus salivarius BLIS M18™ are part of a portfolio of clinically documented bacterial strains for supporting our natural immune defence and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. Blis Technologies’ clinically documented strains have a successful history of use in New Zealand, Australia and Asia, as well as in Europe and in North America.
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.
ABOUT BLIS TECHNOLOGIES
Blis Technologies develops and manufactures advanced probiotic strains outside the field of gastric health. Combining innovation with evidence-based research and the highest quality production controls, enables the delivery of probiotic solutions for specific health areas including ears, nose, throat, halitosis (bad breath), immune health, teeth and gums and skin care. Blis Technologies sells products under both its own brand and through licensing. BLIS® products are sold throughout New Zealand and Australia, Asia, Europe and the USA. The company is listed on NZX. More information about Blis Technologies Ltd can be found at www.blis.co.nz.